A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
about
Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancerChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewRandomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).[A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer].Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachSecond-line chemotherapy for non-small cell lung cancer.Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trialsThe case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Platinum drugs in the treatment of non-small-cell lung cancerLung cancer--where are we today? Current advances in staging and nonsurgical treatment.Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.Docetaxel in non-small cell lung cancer: a review.Lung cancer 7: management of lung cancer in elderly patients.Role of targeted therapy in non-small cell lung cancer: hype or hope?Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.Lung cancer: district active treatment rates affect survival.Gemcitabine (Gemzar) in non-small cell lung cancer.Gefitinib: a new agent in palliative care.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisDocetaxel in advanced non-small cell lung cancer.Combination therapy versus single agent chemotherapy in non-small cell lung cancer.The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer.A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionDomiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors.Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.Cetuximab in non-small cell lung cancer.Docetaxel in the treatment of advanced non-small-cell lung cancer.Age is a prognostic factor affecting survival in lung cancer patients.Effectiveness of palliative care for non-small cell lung cancer.Therapeutic strategy for treatment of metastatic non-small cell lung cancer.BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.Quality-of-life concerns in lung cancer patients.Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.
P2860
Q24235422-F32D5D9A-B0CE-4646-B10B-A97F8968A212Q24643017-6680818A-613F-46CD-846D-B76FB14A8A77Q24678961-C592E717-8274-421F-8232-205364E339FFQ33358448-FAEF7AE7-0538-47B5-A170-6A277760754BQ33401712-13DC4534-A2EE-4DE8-B81A-F49DA66C34DDQ33411167-0FFA6508-9CB8-4558-9DA7-4315F23A8FB8Q33878770-543FC159-16F0-4870-AEBC-7524F9E495C4Q34424790-D0DAE49D-5B80-48BF-A9AD-96ABCF70FCC5Q34650404-24589AFB-5E53-45C6-B85D-7F7221B1AB02Q34791240-06F4AB36-0548-4F58-A024-DAA429D714DDQ34954760-EF48789C-0375-4404-ABD2-7C4ACEA0A096Q34982142-FB302087-DB83-430C-BA3B-D189F31427C7Q35087329-3AB3630A-D78A-4F6C-BF0A-E9623EF71D49Q35095221-3C028C6A-3B88-4305-9243-4C4473C235E6Q35186819-B0861342-4CA8-48B5-87C1-BAA22963F3BEQ35204943-D7FCE0EC-C6FE-4E32-92EA-CF8B754C0F93Q35394529-7A45390F-FA89-4832-906B-A389C349A414Q35408328-1F1BE800-7313-420F-BEFF-21E623AC94DFQ35782899-FB1170A3-A5D7-4A54-8F8F-574A58365201Q35799732-33EE72A6-A824-42F7-804D-2D02770223C8Q36040002-58866CE8-1FC8-485C-977F-49CA336B71D3Q36066126-1D01DE75-4C6F-4402-8B8E-B0766891113EQ36222050-3EC6254A-00C1-4808-8B83-22D7F534C8E9Q36448679-BEF2EE30-1158-454A-8908-A3969BB60B07Q36635810-1B308548-2ABF-46FE-A687-B623E3566E83Q36673578-CA57DEFE-038D-485A-A8DF-781EC96B6A02Q36690369-1C06C665-69E4-4CFD-A43A-0F8186F51DE3Q36788450-DC5DCC4D-4CCE-4651-84B4-C82ADA0EDDCCQ37032651-E2BB3769-B1E5-48BE-9B94-D1CA492EB01DQ37242661-7BD13D13-2D9A-4867-B443-DC35D1CBDC74Q37269229-079CE17C-2D8B-4DE3-8FA4-B37E2D5FAEADQ37288002-3D4FF8D2-666D-45F6-9B69-0F5E8F796BDFQ37310694-939D586B-CE54-45E1-851B-16A7BBC2E5DAQ37396876-EF42E286-4F91-44FF-8F2E-024C74629A38Q37428516-9667C4AC-AC62-4C22-8B7F-1CA297417AF8Q37820679-4A918AB4-B40A-419D-8EE9-D5C313C836F8Q37875561-0002FA7C-8D49-43D2-B807-1AD8C24CCFB0Q37957744-014BA019-CB89-4AD7-B220-2820242E4ADAQ38190461-B6AE8973-F0A0-42FF-A0AE-AF97CF5DA3C8Q38447986-21BB96A0-E2AF-4672-8D8F-D574D9E30560
P2860
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@en
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@nl
type
label
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@en
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@nl
prefLabel
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@en
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@nl
P2093
P1433
P1476
A multicenter, randomized, pha ...... mall cell lung cancer (NSCLC).
@en
P2093
A Pluzanska
K Roszkowski
M Krzakowski
N Pham Tran
R Olivares
P304
P356
10.1016/S0169-5002(00)00094-5
P577
2000-03-01T00:00:00Z